

Fabiola Atzeni

List of Publications by Citations

Source: <https://exaly.com/author-pdf/6858965/fabiola-atzeni-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

203
papers

4,981
citations

37
h-index

63
g-index

228
ext. papers

6,125
ext. citations

5.5
avg, IF

5.71
L-index

#	Paper	IF	Citations
203	The prevalence of fibromyalgia in the general population: a comparison of the American College of Rheumatology 1990, 2010, and modified 2010 classification criteria. <i>Arthritis and Rheumatology</i> , 2015 , 67, 568-75	9.5	232
202	Long-term prognosis and causes of death in systemic lupus erythematosus. <i>American Journal of Medicine</i> , 2006 , 119, 700-6	2.4	215
201	Immunogenicity and autoimmunity during anti-TNF therapy. <i>Autoimmunity Reviews</i> , 2013 , 12, 703-8	13.6	145
200	Autoimmunity and anti-TNF-alpha agents. <i>Annals of the New York Academy of Sciences</i> , 2005 , 1051, 559-69	6.5	135
199	Serious infections during anti-TNFalpha treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009 , 8, 266-73	13.6	134
198	A systematic review and meta-analysis of infection risk with small molecule JAK inhibitors in rheumatoid arthritis. <i>Rheumatology</i> , 2019 , 58, 1755-1766	3.9	128
197	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012 , 12, 225-9	13.6	125
196	TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1173, 837-46	6.5	110
195	Extraspinal manifestations of diffuse idiopathic skeletal hyperostosis. <i>Rheumatology</i> , 2009 , 48, 1478-81	3.9	109
194	TNF-alpha, rheumatoid arthritis, and heart failure: a rheumatological dilemma. <i>Autoimmunity Reviews</i> , 2005 , 4, 153-61	13.6	99
193	Cardiovascular involvement in systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , 2009 , 8, 281-6	13.6	90
192	Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. <i>Autoimmunity Reviews</i> , 2009 , 8, 274-80	13.6	89
191	Etiology of fibromyalgia: the possible role of infection and vaccination. <i>Autoimmunity Reviews</i> , 2008 , 8, 41-3	13.6	88
190	Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study. <i>Arthritis Research and Therapy</i> , 2006 , 8, R3	5.7	88
189	Non-invasive assessment of coronary flow reserve and ADMA levels: a case-control study of early rheumatoid arthritis patients. <i>Rheumatology</i> , 2009 , 48, 834-9	3.9	80
188	Longterm retention of tumor necrosis factor- α inhibitor therapy in a large italian cohort of patients with rheumatoid arthritis from the GISEA registry: an appraisal of predictors. <i>Journal of Rheumatology</i> , 2012 , 39, 1179-84	4.1	80
187	Identification of the clinical features distinguishing psoriatic arthritis and fibromyalgia. <i>Journal of Rheumatology</i> , 2012 , 39, 849-55	4.1	75

186	Clinical and laboratory aspects of Ro/SSA-52 autoantibodies. <i>Autoimmunity Reviews</i> , 2011 , 10, 150-4	13.6	75
185	Fibromyalgia in patients with axial spondyloarthritis: epidemiological profile and effect on measures of disease activity. <i>Rheumatology International</i> , 2014 , 34, 1103-10	3.6	72
184	Chronic widespread pain in the spectrum of rheumatological diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011 , 25, 165-71	5.3	69
183	Different effects of biological drugs in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2013 , 12, 575-9	13.6	66
182	The effect of pharmacological therapy on the cardiovascular system of patients with systemic rheumatic diseases. <i>Autoimmunity Reviews</i> , 2010 , 9, 835-9	13.6	62
181	Fibromyalgia: an update on clinical characteristics, aetiopathogenesis and treatment. <i>Nature Reviews Rheumatology</i> , 2020 , 16, 645-660	8.1	62
180	Cardiac involvement in systemic rheumatic diseases: An update. <i>Autoimmunity Reviews</i> , 2010 , 9, 849-52	13.6	58
179	Five-year follow-up by transesophageal echocardiographic studies in primary antiphospholipid syndrome. <i>American Journal of Cardiology</i> , 2005 , 96, 574-9	3	54
178	Diffuse idiopathic skeletal hyperostosis (DISH): where we are now and where to go next. <i>RMD Open</i> , 2017 , 3, e000472	5.9	53
177	Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. <i>Clinical Reviews in Allergy and Immunology</i> , 2010 , 38, 90-6	12.3	52
176	Anti-cyclic citrullinated peptide antibodies in primary Sjögren syndrome may be associated with non-erosive synovitis. <i>Arthritis Research and Therapy</i> , 2008 , 10, R51	5.7	49
175	Rheumatic manifestations in inflammatory bowel disease. <i>Autoimmunity Reviews</i> , 2014 , 13, 20-3	13.6	48
174	Predicting response to anti-TNF treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009 , 8, 431-7	13.6	47
173	Systemic rheumatic diseases: From biological agents to small molecules. <i>Autoimmunity Reviews</i> , 2019 , 18, 583-592	13.6	45
172	Co-Occurrence and Characteristics of Patients With Axial Spondyloarthritis Who Meet Criteria for Fibromyalgia: Results From a UK National Register. <i>Arthritis and Rheumatology</i> , 2017 , 69, 2144-2150	9.5	44
171	Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. <i>BioDrugs</i> , 2020 , 34, 415-422	7.9	39
170	Potential target of infliximab in autoimmune and inflammatory diseases. <i>Autoimmunity Reviews</i> , 2007 , 6, 529-36	13.6	38
169	Induction of CD69 activation molecule on human neutrophils by GM-CSF, IFN-gamma, and IFN-alpha. <i>Cellular Immunology</i> , 2002 , 220, 20-9	4.4	38

168	Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study. <i>Internal Medicine Journal</i> , 2020 , 50, 1085-1090	1.6	38
167	Low Risk of Hepatitis B Virus Reactivation in HBsAg-negative/Anti-HBc-positive Carriers Receiving Rituximab for Rheumatoid Arthritis: A Retrospective Multicenter Italian Study. <i>Journal of Rheumatology</i> , 2016 , 43, 869-74	4.1	37
166	The effect of tumor necrosis factor-1 antagonists on arterial stiffness in rheumatoid arthritis: a literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2012 , 42, 1-8	5.3	36
165	Coronary flow reserve and asymmetric dimethylarginine levels: new measurements for identifying subclinical atherosclerosis in patients with psoriatic arthritis. <i>Journal of Rheumatology</i> , 2011 , 38, 1661-4	4.1	36
164	Predictive factors of response to rituximab therapy in rheumatoid arthritis: What do we know today?. <i>Autoimmunity Reviews</i> , 2010 , 9, 801-3	13.6	36
163	Silent cardiovascular involvement in patients with diffuse systemic sclerosis: a controlled cross-sectional study. <i>Arthritis Care and Research</i> , 2013 , 65, 274-80	4.7	34
162	Autoantibody production in patients treated with anti-TNF-alpha. <i>Expert Review of Clinical Immunology</i> , 2008 , 4, 275-80	5.1	34
161	How immunological profile drives clinical phenotype of primary Sjögren's syndrome at diagnosis: analysis of 10,500 patients (Sjögren Big Data Project). <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 112, 102-112	2.2	34
160	Development and validation of the self-administered Fibromyalgia Assessment Status: a disease-specific composite measure for evaluating treatment effect. <i>Arthritis Research and Therapy</i> , 2009 , 11, R125	5.7	33
159	Interstitial lung disease in systemic autoimmune rheumatic diseases: a comprehensive review. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 69-82	5.1	33
158	Failure of anti-TNF treatment in patients with rheumatoid arthritis: The pros and cons of the early use of alternative biological agents. <i>Autoimmunity Reviews</i> , 2019 , 18, 102398	13.6	32
157	Multidisciplinary approach to fibromyalgia: what is the teaching?. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011 , 25, 311-9	5.3	32
156	Correlation of the score for subjective pain with physical disability, clinical and radiographic scores in recent onset rheumatoid arthritis. <i>BMC Musculoskeletal Disorders</i> , 2002 , 3, 18	2.8	32
155	How to handle patients with autoimmune rheumatic and inflammatory bowel diseases in the COVID-19 era: An expert opinion. <i>Autoimmunity Reviews</i> , 2020 , 19, 102574	13.6	29
154	Lung involvement and drug-induced lung disease in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2013 , 9, 649-57	5.1	29
153	From autoinflammation to autoimmunity: old and recent findings. <i>Clinical Rheumatology</i> , 2018 , 37, 2305-2321	5.3	28
152	Long-term safety of abatacept in patients with rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2013 , 12, 1115-7	13.6	28
151	Switching rheumatoid arthritis treatments: an update. <i>Autoimmunity Reviews</i> , 2011 , 10, 397-403	13.6	28

150	The heart in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2010 , 9, 414-8	13.6	28
149	TNF inhibitors in rheumatoid arthritis and spondyloarthritis: Are they the same?. <i>Autoimmunity Reviews</i> , 2018 , 17, 24-28	13.6	28
148	Is fibromyalgia a discrete entity?. <i>Autoimmunity Reviews</i> , 2012 , 11, 585-8	13.6	27
147	Etanercept plus ciclosporin versus etanercept plus methotrexate for maintaining clinical control over psoriatic arthritis: a randomised pilot study. <i>Annals of the Rheumatic Diseases</i> , 2011 , 70, 712-4	2.4	25
146	Safety of Biologics, Including Biosimilars: Perspectives on Current Status and Future Direction. <i>Drug Safety</i> , 2018 , 41, 1013-1022	5.1	25
145	Early treatment in early undifferentiated arthritis. <i>Autoimmunity Reviews</i> , 2012 , 11, 589-92	13.6	24
144	Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis. <i>Biologics: Targets and Therapy</i> , 2013 , 7, 69-75	4.4	24
143	Are the ACR 2010 diagnostic criteria for fibromyalgia better than the 1990 criteria?. <i>Autoimmunity Reviews</i> , 2018 , 17, 33-35	13.6	24
142	EULAR recommendations for management of fibromyalgia. <i>Annals of the Rheumatic Diseases</i> , 2017 , 76, e54	2.4	23
141	Il-6 Involvement in pain, fatigue and mood disorders in rheumatoid arthritis and the effects of Il-6 inhibitor sarilumab. <i>Pharmacological Research</i> , 2019 , 149, 104402	10.2	23
140	Safety of Abatacept in Italian Patients with Rheumatoid Arthritis and Interstitial Lung Disease: A Multicenter Retrospective Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	23
139	What is the role of rituximab in the treatment of rheumatoid arthritis?. <i>Autoimmunity Reviews</i> , 2007 , 6, 553-8	13.6	23
138	Central nervous system involvement in rheumatoid arthritis patients and the potential implications of using biological agents. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018 , 32, 500-510	5.3	23
137	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology I. Efficacy. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, S7-14	2.2	23
136	Measuring psoriatic disease in clinical practice. An expert opinion position paper. <i>Autoimmunity Reviews</i> , 2015 , 14, 864-74	13.6	22
135	Infections in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2017 , 29, 323-330	5.3	21
134	Investigating the potential side effects of anti-TNF therapy for rheumatoid arthritis: cause for concern?. <i>Immunotherapy</i> , 2015 , 7, 353-61	3.8	21
133	Pain in systemic inflammatory rheumatic diseases. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015 , 29, 42-52	5.3	21

132	Anti-cytokine antibodies for rheumatic diseases. <i>Current Opinion in Investigational Drugs</i> , 2009 , 10, 1204-11		21
131	Subclinical and clinical atherosclerosis in rheumatoid arthritis: results from the 3-year, multicentre, prospective, observational GIRRCs (Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale) study. <i>Arthritis Research and Therapy</i> , 2019 , 21, 204	5.7	19
130	Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28 scores. <i>Joint Bone Spine</i> , 2014 , 81, 37-40	2.9	19
129	Disease Severity in Never Smokers, Ex-Smokers, and Current Smokers With Axial Spondyloarthritis: Results From the Scotland Registry for Ankylosing Spondylitis. <i>Arthritis Care and Research</i> , 2017 , 69, 1407-1413 ¹⁸	4.7	18
128	A Review of Chronic Musculoskeletal Pain: Central and Peripheral Effects of Diclofenac. <i>Pain and Therapy</i> , 2018 , 7, 163-177	3.6	18
127	Combined therapeutic approach: inflammatory bowel diseases and peripheral or axial arthritis. <i>World Journal of Gastroenterology</i> , 2009 , 15, 2469-71	5.6	18
126	Identifying the symptom and functional domains in patients with fibromyalgia: results of a cross-sectional Internet-based survey in Italy. <i>Journal of Pain Research</i> , 2016 , 9, 279-86	2.9	18
125	Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified Fibromyalgia Assessment Status. <i>Rheumatology</i> , 2020 , 59, 3042-3049	3.9	17
124	Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. <i>International Journal of Rheumatic Diseases</i> , 2018 , 21, 422-430	2.3	17
123	Clinimetric evaluations of patients with chronic widespread pain. <i>Best Practice and Research in Clinical Rheumatology</i> , 2011 , 25, 249-70	5.3	16
122	Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCs) cohort. <i>PLoS ONE</i> , 2020 , 15, e0235326	3.7	15
121	Influence of co-morbid fibromyalgia on disease activity measures and response to tumour necrosis factor inhibitors in axial spondyloarthritis: results from a UK national register. <i>Rheumatology</i> , 2018 , 57, 1982-1990	3.9	15
120	Doctors' insights into the patient perspective: a qualitative study in the field of chronic pain. <i>BioMed Research International</i> , 2014 , 2014, 514230	3	15
119	How to measure chronic pain: New concepts. <i>Best Practice and Research in Clinical Rheumatology</i> , 2015 , 29, 164-86	5.3	14
118	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , 2016 , 35, 2649-2656 ¹⁴	3.9	14
117	Parenchymal lung disease in adult onset Still's disease: an emergent marker of disease severity-characterisation and predictive factors from Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCs) cohort of patients. <i>Arthritis Research and Therapy</i> , 2020 , 22, 151	5.7	13
116	Preclinical impairment of coronary flow reserve in patients with rheumatoid arthritis. <i>Annals of the New York Academy of Sciences</i> , 2007 , 1108, 392-7	6.5	13
115	Efficacy of ketoprofen vs. ibuprofen and diclofenac: a systematic review of the literature and meta-analysis. <i>Clinical and Experimental Rheumatology</i> , 2013 , 31, 731-8	2.2	13

114	Italian consensus Guidelines for the management of hepatitis B virus infections in patients with rheumatoid arthritis. <i>Joint Bone Spine</i> , 2017 , 84, 525-530	2.9	12
113	Psoriatic arthritis: From pathogenesis to pharmacologic management. <i>Pharmacological Research</i> , 2019 , 148, 104394	10.2	12
112	Usefulness of cardiovascular biomarkers and cardiac imaging in systemic rheumatic diseases. <i>Autoimmunity Reviews</i> , 2010 , 9, 845-8	13.6	12
111	Cardiovascular effects of approved drugs for rheumatoid arthritis. <i>Nature Reviews Rheumatology</i> , 2021 , 17, 270-290	8.1	12
110	Imaging of diffuse idiopathic skeletal hyperostosis (DISH). <i>RMD Open</i> , 2020 , 6,	5.9	12
109	The Key Comorbidities in Patients with Rheumatoid Arthritis: A Narrative Review. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	12
108	Medical cannabis and cannabinoids in rheumatology: where are we now?. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 1019-1032	5.1	11
107	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018 , 85, 455-459	2.9	11
106	The role of echocardiographic techniques in connective tissue diseases. <i>Autoimmunity Reviews</i> , 2005 , 4, 171-7	13.6	11
105	Correlations between immunogenicity, drug levels, and disease activity in an Italian cohort of rheumatoid arthritis patients treated with tocilizumab. <i>Biologics: Targets and Therapy</i> , 2016 , 10, 53-8	4.4	11
104	The influence of comorbidities on the efficacy of tumour necrosis factor inhibitors, and the effect of tumour necrosis factor inhibitors on comorbidities in rheumatoid arthritis: report from a National Consensus Conference. <i>Rheumatology</i> , 2018 , 57, vii11-vii22	3.9	11
103	Successful treatment of pure red cell aplasia in systemic lupus erythematosus with cyclosporin A. <i>Clinical and Experimental Rheumatology</i> , 2003 , 21, 759-62	2.2	11
102	Adverse events, clinical considerations and management recommendations in rheumatoid arthritis patients treated with JAK inhibitors. <i>Expert Review of Clinical Immunology</i> , 2018 , 14, 945-956	5.1	10
101	Accelerated subcutaneous nodulosis in patients with rheumatoid arthritis treated with tocilizumab: a case series. <i>Journal of Medical Case Reports</i> , 2018 , 12, 154	1.2	10
100	An update on emerging drugs for fibromyalgia treatment. <i>Expert Opinion on Emerging Drugs</i> , 2017 , 22, 357-367	3.7	10
99	Serological epitope profile of anti-Ro52-positive patients with systemic autoimmune rheumatic diseases. <i>Arthritis Research and Therapy</i> , 2015 , 17, 365	5.7	10
98	CC chemokine receptor 5 polymorphism in Italian patients with Behcet's disease. <i>Rheumatology</i> , 2012 , 51, 2141-5	3.9	10
97	Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity. <i>Annals of Laboratory Medicine</i> , 2020 , 40, 101-113	3.1	10

96	Cardiovascular risk in ankylosing spondylitis and the effect of anti-TNF drugs: a narrative review. <i>Expert Opinion on Biological Therapy</i> , 2020 , 20, 517-524	5.4	10
95	Prescribing motivations and patients' characteristics related to the use of biologic drugs in adult-onset Still's disease: analysis of a multicentre "real-life" cohort. <i>Rheumatology International</i> , 2020 , 40, 107-113	3.6	10
94	Diffuse Idiopathic Skeletal Hyperostosis (DISH) and a Possible Inflammatory Component. <i>Current Rheumatology Reports</i> , 2021 , 23, 6	4.9	10
93	Pain in Women: A Perspective Review on a Relevant Clinical Issue that Deserves Prioritization. <i>Pain and Therapy</i> , 2021 , 10, 287-314	3.6	9
92	One year in review 2019: fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 116, 3-10	2.2	9
91	Rate of serious infections in spondyloarthropathy patients treated with anti-tumour necrosis factor drugs: a survey from the Italian registry GISEA. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37, 649-655	2.2	9
90	Role of Agents other than Tumor Necrosis Factor Blockers in the Treatment of Psoriatic Arthritis. <i>Journal of rheumatology Supplement, The</i> , 2015 , 93, 79-81		8
89	The Neuropathic Pain Features in Psoriatic Arthritis: A Cross-sectional Evaluation of Prevalence and Associated Factors. <i>Journal of Rheumatology</i> , 2020 , 47, 1198-1203	4.1	8
88	Concerns about the safety of anti-TNF agents when treating rheumatic diseases. <i>Expert Opinion on Drug Safety</i> , 2020 , 19, 695-705	4.1	8
87	A possible link between ankylosing spondylitis and periodontitis: a systematic review and meta-analysis. <i>Rheumatology</i> , 2015 , 54, 500-10	3.9	8
86	Twelve years' experience with etanercept in the treatment of rheumatoid arthritis: how it has changed clinical practice. <i>Expert Review of Clinical Immunology</i> , 2012 , 8, 213-22	5.1	8
85	Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up. <i>Autoimmunity</i> , 2008 , 41, 87-91	3	8
84	Comparison of Efficacy of Ketoprofen and Ibuprofen in Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis. <i>Pain and Therapy</i> , 2021 , 10, 577-588	3.6	8
83	The Rheumatology Drugs for COVID-19 Management: Which and When?. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	8
82	Rheumatic diseases and autoimmune vascular dementia. <i>Autoimmunity Reviews</i> , 2017 , 16, 1265-1269	13.6	7
81	Building bridges between doctors and patients: the design and pilot evaluation of a training session in argumentation for chronic pain experts. <i>BMC Medical Education</i> , 2015 , 15, 89	3.3	7
80	Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry. <i>BioMed Research International</i> , 2014 , 2014, 416892	3	7
79	Determinants of Risk Infection During Therapy with Anti TNF-Alpha Blocking Agents in Rheumatoid Arthritis. <i>Open Rheumatology Journal</i> , 2012 , 6, 33-7	0.2	7

78	Microbial Agents as Putative Inducers of B Cell Lymphoma in Sjögren's Syndrome through an Impaired Epigenetic Control: The State-of-The-Art. <i>Journal of Immunology Research</i> , 2019 , 2019, 8567364	4.5	7
77	Safety and effectiveness of biosimilar of Rituximab CT-P10 in the treatment of cryoglobulinemic vasculitis: the MARBLE study (Mixed cryoglobulinemia Rituximab Biosimilar). <i>Internal and Emergency Medicine</i> , 2021 , 16, 149-156	3.7	7
76	Dissecting the clinical heterogeneity of adult-onset Still's disease: results from a multi-dimensional characterization and stratification. <i>Rheumatology</i> , 2021 , 60, 4844-4849	3.9	7
75	Assessment of enthesitis in patients with psoriatic arthritis and fibromyalgia using clinical examination and ultrasound. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 123, 31-39	2.2	7
74	Malar rash is a predictor of subclinical airway inflammation in patients with systemic lupus erythematosus: a pilot study. <i>Clinical Rheumatology</i> , 2019 , 38, 2541-2546	3.9	6
73	Severe bitter taste associated with apremilast. <i>Dermatologic Therapy</i> , 2019 , 32, e12876	2.2	6
72	EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	6
71	Extra-intestinal manifestations of inflammatory bowel diseases. <i>Pharmacological Research</i> , 2020 , 161, 105206	10.2	6
70	Adding medical cannabis to standard analgesic treatment for fibromyalgia: a prospective observational study. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 123, 53-59	2.2	6
69	The contribution of HERV-E clone 4-1 and other HERV-E members to the pathogenesis of rheumatic autoimmune diseases. <i>Apmis</i> , 2020 , 128, 367-377	3.4	5
68	Novel pharmaceutical options for treating fibromyalgia. <i>Expert Review of Clinical Pharmacology</i> , 2016 , 9, 559-565	3.8	5
67	Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies?. <i>Autoimmunity Reviews</i> , 2019 , 18, 102401	13.6	5
66	Biological Agents in Rheumatoid Arthritis: A Cross-Link Between Immune Tolerance and Immune Surveillance. <i>Current Rheumatology Reviews</i> , 2018 , 14, 131-139	1.6	5
65	Cross Cultural Adaptation and Validation of Italian Version of the Leeds Assessment of Neuropathic Symptoms and Signs Scale and Pain DETECT Questionnaire for the Distinction between Nociceptive and Neuropathic Pain. <i>Pain Research and Management</i> , 2021 , 2021, 6623651	2.6	5
64	Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. <i>Rheumatology</i> , 2021 , 60, SI25-SI36	3.9	5
63	Cannabis and Autoimmunity: Possible Mechanisms of Action. <i>ImmunoTargets and Therapy</i> , 2021 , 10, 261-271	3.71	5
62	Is central sensitization an important determinant of functional disability in patients with chronic inflammatory arthritides?. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021 , 13, 1759720X21993252	3.8	5
61	Usefulness of six-minute walk test in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36 Suppl 113, 161-167	2.2	5

60	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 186-193	2.2	5
59	Safety Profile of Biologics Used in Rheumatology: An Italian Prospective Pharmacovigilance Study. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	4
58	Noninvasive imaging methods for evaluating cardiovascular involvement in patients with rheumatoid arthritis before and after anti-TNF drug treatment. <i>Future Science OA</i> , 2019 , 5, FSO396	2.7	4
57	Resistant cases of psoriatic arthritis: how to manage them. <i>Journal of rheumatology Supplement, The</i> , 2009 , 83, 73-5		4
56	Differences between diffuse idiopathic skeletal hyperostosis and spondyloarthritis. <i>Immunotherapy</i> , 2020 , 12, 749-756	3.8	4
55	Behçet disease: From pathogenesis to novel therapeutic options. <i>Pharmacological Research</i> , 2021 , 167, 105593	10.2	4
54	Definition of fibromyalgia severity: findings from a cross-sectional survey of 2339 Italian patients. <i>Rheumatology</i> , 2021 , 60, 728-736	3.9	4
53	New biological treatments for psoriatic arthritis. <i>Israel Medical Association Journal</i> , 2014 , 16, 643-5	0.9	4
52	Systemic manifestations of primary Sjögren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 97-106	2.2	4
51	Cardiovascular Imaging Techniques in Systemic Rheumatic Diseases. <i>Frontiers in Medicine</i> , 2018 , 5, 26	4.9	3
50	Biosimilars vs originators: Are they the same?. <i>Autoimmunity Reviews</i> , 2019 , 18, 102404	13.6	3
49	Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis. <i>ImmunoTargets and Therapy</i> , 2021 , 10, 141-153	9	3
48	The effect of drugs used in rheumatology for treating SARS-CoV2 infection. <i>Expert Opinion on Biological Therapy</i> , 2021 , 21, 219-228	5.4	3
47	Hyperbaric oxygen treatment of fibromyalgia: a prospective observational clinical study. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 116, 63-69	2.2	3
46	Hyperbaric oxygen therapy in fibromyalgia and the diseases involving the central nervous system. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 123, 94-98	2.2	3
45	The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 130, 72-77	2.2	3
44	One year in review 2021: fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 3-12	2.2	3
43	Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study. <i>Biologics: Targets and Therapy</i> , 2020 , 14, 13-21	4.4	2

42	Controlled-release pregabalin in the treatment of fibromyalgia. <i>Expert Review of Neurotherapeutics</i> , 2018 , 18, 617-623	4.3	2
41	Safety of JAK inhibitors: focus on cardiovascular and thromboembolic events.. <i>Expert Review of Clinical Immunology</i> , 2022 ,	5.1	2
40	Cancer risk and tumour necrosis factor inhibitors in patients with inflammatory arthritis. <i>Pharmacological Research</i> , 2020 , 158, 104507	10.2	2
39	Anti-adalimumab and anti-certolizumab antibodies titers after discontinuation of adalimumab: two case reports. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020 , 58, e105-e108	5.9	2
38	Acute and chronic pain in orthopaedic and rheumatologic diseases: mechanisms and characteristics. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35 Suppl 105, 127-131	2.2	2
37	Toxicological considerations in the treatment of axial spondylo-arthritis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2020 , 16, 663-672	5.5	1
36	Therapeutic peptides for the treatment of systemic lupus erythematosus: a place in therapy. <i>Expert Opinion on Investigational Drugs</i> , 2020 , 29, 845-867	5.9	1
35	Recurrent intracranial hemorrhage and cerebral venous sinus thrombosis: an atypical case of Neuro-Behçet's Syndrome. <i>Clinical Neurology and Neurosurgery</i> , 2020 , 191, 105680	2	1
34	Retrotransposons shuttling genetic and epigenetic information from the nuclear to the mitochondrial compartment: Do they play a pathogenetic role in scleroderma?. <i>Cytokine and Growth Factor Reviews</i> , 2019 , 49, 42-58	17.9	1
33	Autoimmunity and the Newer Biopharmaceuticals 2014 , 795-802		1
32	Cardiovascular Consequences of Autoimmune Rheumatic Diseases. <i>Current Vascular Pharmacology</i> , 2020 , 18, 566-579	3.3	1
31	Impact of smoking habit on adult-onset Still's disease prognosis, findings from a multicentre observational study. <i>Clinical Rheumatology</i> , 2021 , 1	3.9	1
30	Comment on: Diagnosis of fibromyalgia: comparison of the 2011/2016 ACR and AAPT criteria and validation of the modified Fibromyalgia Assessment Status: reply. <i>Rheumatology</i> , 2020 , 59, e81	3.9	1
29	Psoriatic Arthritis and Metabolic Syndrome: Is There a Role for Disease Modifying Anti-Rheumatic Drugs?. <i>Frontiers in Medicine</i> , 2021 , 8, 735150	4.9	1
28	Antifibrotic drugs in connective tissue disease-related interstitial lung disease (CTD-ILD): from mechanistic insights to therapeutic applications. <i>Drugs in Context</i> , 2021 , 10,	5.2	1
27	Evaluation of salivary and plasma microRNA expression in patients with Sjögren's syndrome, and correlations with clinical and ultrasonographic outcomes. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 118, 70-77	2.2	1
26	Neuromuscular efficiency in fibromyalgia is improved by hyperbaric oxygen therapy: looking inside muscles by means of surface electromyography. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 116, 75-80	2.2	1
25	Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 245-256	2.2	1

24	Systemic phenotype related to primary Sjögren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38 Suppl 126, 85-94	2.2	1
23	Fibromyalgia position paper. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 130, 186-193	2.2	1
22	One year in review 2021: fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39 Suppl 130, 3-12	2.2	1
21	Study of entheses in patients with spondyloarthritis and inflammatory bowel disease with and without fibromyalgia: The importance of ultrasonography. <i>Joint Bone Spine</i> , 2020 , 87, 507-508	2.9	0
20	Rheumatoid Arthritis disease activity assessment in routine care: performance of the most widely used composite disease activity indices and patient-reported outcome measures. <i>Acta Biomedica</i> , 2021 , 92, e2021238	3.2	0
19	Differences in depression, anxiety and stress disorders between fibromyalgia associated with rheumatoid arthritis and primary fibromyalgia. <i>Stress and Health</i> , 2021 , 37, 255-262	3.7	0
18	The association between body mass index and fibromyalgia severity: data from a cross-sectional survey of 2339 patients. <i>Rheumatology Advances in Practice</i> , 2021 , 5, rkab015	1.1	0
17	Rationale underlying the measurement of fractional exhaled nitric oxide in systemic sclerosis patients. <i>Clinical and Experimental Rheumatology</i> , 2019 , 37 Suppl 119, 125-132	2.2	0
16	Occurrence and predictive factors of high blood pressure, type 2 diabetes, and metabolic syndrome in rheumatoid arthritis: findings from a 3-year, multicentre, prospective, observational study. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 995-1002	2.2	0
15	Diagnostic and therapeutic care pathway for fibromyalgia. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 120-127	2.2	0
14	Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium. <i>Clinical and Experimental Rheumatology</i> , 2021 , 39, 166-174	2.2	0
13	Prédicteurs de la réponse aux traitements anti-TNF chez les patients ayant une polyarthrite rhumatoïde avec des scores DAS28 modifiés ou élevés. <i>Revue Du Rhumatisme (Edition Française)</i> , 2014 , 81, 54-57	0.1	
12	Helicobacter pylori Infection and Gastric Autoimmunity 2015 , 495-503		
11	Echocardiographic approach in systemic autoimmune diseases. <i>Journal of Cardiovascular Echography</i> , 2011 , 21, 152-156	0.6	
10	La sindrome fibromialgica: dalla diagnosi alla terapia. <i>L Endocrinologo</i> , 2019 , 20, 361-369	0	
9	PLA1/A2 polymorphism of the platelet glycoprotein receptors IIIA in Behçet's disease. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, S38-43	2.2	
8	Metabolic Syndrome in Systemic Sclerosis Patients: Data from Clinical Practice. <i>Israel Medical Association Journal</i> , 2021 , 23, 262-263	0.9	
7	Efficacy and Safety of Biosimilar and Originator Etanercept in Rheumatoid Arthritis Patients: Real-Life Data. <i>Israel Medical Association Journal</i> , 2021 , 23, 344-349	0.9	

- 6 Diagnostic and therapeutic care pathway for fibromyalgia. *Clinical and Experimental Rheumatology*, **2021**, 39 Suppl 130, 120-127 2.2
- 5 Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort **2020**, 15, e0235326
- 4 Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort **2020**, 15, e0235326
- 3 Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort **2020**, 15, e0235326
- 2 Ferritin and C-reactive protein are predictive biomarkers of mortality and macrophage activation syndrome in adult onset Still's disease. Analysis of the multicentre Gruppo Italiano di Ricerca in Reumatologia Clinica e Sperimentale (GIRRCS) cohort **2020**, 15, e0235326
- 1 Influence of the age at diagnosis in the disease expression of primary Sjögren syndrome. Analysis of 12,753 patients from the Sjögren Big Data Consortium.. *Clinical and Experimental Rheumatology*, **2021**, 39 Suppl 133, 166-174 2.2